Actin stabilizing compounds show specific biological effects due to their binding mode

Shuaijun Wang1, Alvaro H. Crevenna2,6, Ilke Ugur3, Antoine Marion3, Iris Antes1, Uli Kazmaier4, Maria Hoyer1,6, Don C. Lamb2, Florian Gegenfurtner1, Zane Kliesmete5, Christoph Ziegenhain5, Wolfgang Enard6, Angelika Vollmar2 & Stefan Zahler1

Actin binding compounds are widely used tools in cell biology. We compare the biological and biochemical effects of miuraenamide A and jasplakinolide, a structurally related prototypic actin stabilizer. Though both compounds have similar effects on cytoskeletal morphology and proliferation, they affect migration and transcription in a distinctive manner, as shown by a transcriptome approach in endothelial cells. In vitro, miuraenamide A acts as an actin nucleating, F-actin polymerizing and stabilizing compound, just like described for jasplakinolide. However, in contrast to jasplakinolide, miuraenamide A competes with cofilin, but not gelsolin or Arp2/3 for binding to F-actin. We propose a binding mode of miuraenamide A, explaining both its similarities and its differences to jasplakinolide. Molecular dynamics simulations suggest that the bromophenol group of miurenamide A interacts with residues Tyr133, Tyr143, and Phe352 of actin. This shifts the D-loop of the neighboring actin, creating tighter packing of the monomers, and occluding the binding site of cofilin. Since relatively small changes in the molecular structure give rise to this selectivity, actin binding compounds are surprisingly promising scaffolds for creating actin binders with specific functionality instead of just "stabilizers".

Actin is the most abundant protein in eukaryotic cells and plays a central role in many processes such as cell migration, cell division and intracellular transport. The discovery of actin binding compounds (cytochalasin D 19711, phalloidin 19752, latrunculin 19833, jasplakinolide 19944) has immensely fueled our knowledge about the biology of actin, and the natural compounds mentioned above have become standard tools in cell biology. To date, small actin-binding molecules are roughly divided into two groups: destabilizers (like e.g. latrunculin or cytochalasin D), and stabilizers (like e.g. phalloidin or jasplakinolide). However, during the past years, we have learned that the complexity of actin biology goes far beyond the regulation of overall polymerization and depolymerization5: actin does not merely form polymers with other actin molecules and subsequently depolymerize again. Rather, actin binding proteins continuously compete with each other for binding sites on actin (e.g. thymosin beta4 with profilin6, or MRTF with G-actin7) and with actin itself5. This complex network allows for subtle control of the "actin-interactome" and related cell functions. Small actin-binding molecular compounds have been found to, in turn, compete with specific actin-binding proteins. For example, kabiramide C has been shown to compete with actin capping proteins like gelsolin in a kind of "molecular mimicry"8. This aspect of the interaction between small molecular inhibitors and actin has been largely neglected during their discovery and characterization. Therefore, the effects of actin-binding compounds on the cellular level (where the complex nature of the cytoplasm has to be considered) might, at least in part, be caused by mechanisms that have not yet been thoroughly considered.

The myxobacterial compound miuraenamide A (MiuA) is structurally related to the classical actin stabilizer jasplakinolide. Accordingly, it has been presumed to also be an actin filament stabilizing agent8,10. Our in depth
characterization of MiuA shows many similarities to jasplakinolide on a cellular and in vitro level. However, in the context of protein–protein interactions and transcriptional regulation MiuA shows striking functional differences to jasplakinolide, which can be in part explained by the unique binding mode we suggest.

Results

MiuA inhibits proliferation of endothelial cells at nanomolar concentrations and leads to actin aggregation. To assess the effect of MiuA on cells, we first measured proliferation. At nanomolar concentrations, MiuA inhibited the proliferation of HUVEC (human umbilical vein endothelial cells) with an IC50 value of around 9 nM (Fig. 1a), which is comparable to that in tumor cell lines (HCT116, HepG2, HL-60, U-2OS)4. Phalloidin staining of F-actin revealed that one hour of incubation with 30 nM of MiuA reorganizes the actin cytoskeleton into clusters or aggregates (Fig. 1b). At 100 nM MiuA, the actin cytoskeleton was completely destroyed and perinuclear actin aggregates were observed (Fig. 1b).

MiuA inhibits HUVEC cell migration. To examine the effect of MiuA on the ability of cells to migrate, we performed a scratch assay. The migration of HUVEC cells was inhibited by MiuA in a concentration-dependent manner with an IC50 of approximately 80 nM (Fig. 1c). Since migration normally occurs in a gradient of growth factors, we studied the effect of MiuA on the chemotactic properties of HUVECs. In a 2D-chemotaxis assay, the directed migration of HUVECs was inhibited by 10 nM MiuA, as seen by the reduction of the forward migration index (FMI) and directness, while the mean velocity of movement was not affected (Fig. 1d). In 3D-chemotaxis, at 10 nM MiuA, cell migration directness, mean velocity and FMI were all significant reduced (Fig. 1e). These results indicate that MiuA has an overall effect on both cell motility and directionality of the movement, both in a simple 2D and in more physiological 3D environments. The reduced velocity in the 3D system could be explained by the cells having a reduced ability to squeeze through a small meshwork, as we have previously described11.

Overall, the cellular response to MiuA was typical for actin nucleating compounds12.

MiuA and jasplakinolide differentially regulate gene expression. Treatment of HUVECs with a well tolerated concentration of MiuA (60 nM) or equipotent concentration of jasplakinolide (120 nM) for 4 h caused dramatic effects on transcriptional regulation. With MiuA 779 genes were significantly regulated, with jasplakinolide 224 genes compared to untreated control (FDR < 0.1) (Table 1). The direct comparison between the two treatments revealed 101 significantly differentially expressed genes (Supplementary Table 1). When the regulated genes are classified into functionally relevant gene ontologies (Supplementary Table 2 for MiuA and Supplementary Table 3 for jasplakinolide), it becomes clear that most of the differences between MiuA treatment and jasplakinolide do not result from different extents of regulation of the same genes, but from regulation of different sets of genes. Differentially expressed genes between the two conditions were used for gene set enrichment analysis. The 20 most significantly enriched biological processes can be seen in Table 2. 12 of these are unique for this comparison (highlighted in grey) and are not affected by either treatment alone vs. control.

Effects of MiuA on the binding of proteins to G-actin. We next investigated whether MiuA affects the binding of actin binding proteins (ABPs) to G-actin. To this end, we performed pulldown experiments with G-actin immobilized on beads and added single ABPs (gelsolin, profilin, cofilin and Arp2/3 complex with GST-VCA). As depicted in Fig. 2a–d, the total amount of the tested ABPs in G-actin pellets did not increase or decrease even if treated with a high amount of MiuA (50 or 100 fold excess), indicating that MiuA does not compete with gelsolin, profilin, cofilin or Arp2/3 complex for binding to G-actin. Detection of competitive effects in this assay was proven to be possible by showing the competition between cofilin and gelsolin (Supplementary Fig. 1c).

In contrast to jasplakinolide, MiuA influences cofilin binding to F-actin. To investigate potential competition of MiuA and ABPs for binding to F-actin, we also performed a binding assay with cofilin, gelsolin and Arp2/3 complex (together with GST-VCA) to F-actin. In the absence of MiuA, cofilin was largely found in the F-actin pellet (Fig. 3a), as expected from the known interaction between cofilin and F-actin. In the presence of MiuA, a significant reduction of cofilin was observed in the pellet (Fig. 3a, upper panel). Jasplakinolide did not change binding of cofilin to F-actin, even when added at a ten-fold concentration in comparison to MiuA (Fig. 3a, lower panel). Neither MiuA nor jasplakinolide seem to influence binding of gelsolin (Fig. 3b) to F-actin. However, it has to be taken into account that gelsolin has an F-actin severing activity, which shows by a shift of actin into the supernatant fraction (Fig. 3b). Thus, the experimental situation is quite complex and we can only comment on the binding of gelsolin to the F-actin remaining in the pellet fraction. MiuA did not affect Arp2/3 complex binding to F-actin, since the amounts of Arp2/3 complex in F-actin pellet were similar in the presence or absence of MiuA (Fig. 3c). These results suggest that MiuA selectively interferes with the binding of cofilin to F-actin, and that this action is specific for MiuA, since it was not mimicked by jasplakinolide. The inhibition of cofilin binding to F-actin by MiuA also seems to work in the cellular context, since treatment of HUVECs with 50 nM MiuA for 30 min reduced co-localization of cofilin with F-actin, as shown by confocal microscopy (Supplementary Fig. 2).

Miuraenamide A induces actin nucleation and polymerization, as well as stabilization of filaments. Based on previous findings15, we investigated the molecular mechanism of the interaction of miuraenamide A (MiuA) with actin alone. First, we examined the effect of MiuA on the actin polymerization process in a pyrene assay. With 1 μM MiuA, actin nucleation and polymerization was faster (Fig. 4a) but, interestingly, peak fluorescence was lower. This might result from substrate consumption by the rapid formation of small actin aggregates. Monitoring actin filament assembly by TIRF (total internal reflection fluorescence) microscopy showed that MiuA increased the overall rate of formation of actin filaments (Fig. 4b). This increase in the number of
Figure 1. MiuA inhibits proliferation of HUVEC cells, induces actin aggregation and inhibits migration. (a) Half inhibitory concentration (IC₅₀) of MiuA on proliferation (n = 3). (b) Actin morphology of HUVEC cells after treatment with the indicated concentrations of MiuA for 1 h: F-actin (phodamine phalloidin, red) and nuclei (Hoechst, blue). Representative images of 3 independent experiments performed in triplicates are shown. Upper panel: scale bar represents 75 µm, lower panel: zoomed sections from images above, scale bar represents 30 µm. The white frame indicates the zoomed in area. (c) Confluent HUVECs were scratched and treated with MiuA (indicated concentrations). After 16 h, images were collected and the cell covered area was analyzed. Left panel: the measured IC₅₀ of MiuA from a scratch assay is shown (n = 3). Right panel: Representative images of the scratch assay. The scale bar represents 200 µm. MiuA inhibits endothelial cells migration (d) in 2D- and (e) in 3D-chemotaxis assays. Quantitative evaluation of the parameters X-Forward migration index, directness and mean velocity are shown (n = 3). Analysis of one representative experiment (out of triplicates in three independent experiments) is shown. (Kruskal–Wallis test with Dunns test as post hoc, *P < 0.05, **P < 0.01 vs. control, n = 3).
filaments formed over time suggested a stabilizing effect during nucleation. We also monitored the formation of oligomers by Fluorescence Fluctuation Spectroscopy 13. The appearance of spikes in the data represent stabilized oligomers13. Addition of MiuA to actin below the critical concentration for filament assembly (cc = 200 nM) showed an increase in the appearance and size of large oligomers over 1 h (Fig. 4c). To investigate the formation of small oligomers, we calculated the autocorrelation function in regions where no spikes were observable. The appearance of a second diffusing species with a significantly longer diffusion time indicates formation of small nuclei with MiuA (Fig. 4c). These results suggest that MiuA favors polymerization by stabilizing the early stage oligomers formed during nucleation.

Next, we investigated the influence of MiuA on the rate of actin filament elongation using TIRF microscopy. In the absence and presence of 250 nM of MiuA, we monitored the length of individual filaments as a function of time and found that the elongation rate doubled compared to control samples (Fig. 4d). To determine whether MiuA plays any role in stabilizing actin filaments, we monitored the disassembly of labeled actin filaments in the presence and absence of 5 μM MiuA by TIRF microscopy. As expected, the length of actin filaments decreased in a time-dependent manner in the absence of MiuA. In the presence of MiuA, disassembly of filaments was retarded (Fig. 5a). These results indicate that the binding of MiuA promotes both, the assembly and stabilization of actin filaments.

MiuA competes with phalloidin for binding to F-actin. Phalloidin is a classical F-actin stabilizing compound with a well characterized binding site14. To investigate whether MiuA binding to actin competes with phalloidin binding, we performed a competition assay with rhodamine labeled phalloidin. Rhodamine-labeled phalloidin could be displaced from actin filaments by MiuA in a concentration dependent manner (Fig. 5b) with an IC50 of about 5 nM (Fig. 5b, right panel). This indicates that MiuA may share a proximal binding site with phalloidin on F-actin, or that MiuA allosterically influences binding of phalloidin.

MiuA tightens actin monomer assembly and hinders binding of cofilin by shifting the D-loop. Since the binding mode of MiuA is still unknown, we investigated the atomic details of possible docking sites. Five possible binding sites for MiuA were suggested from the docking computations (Fig. 6a) performed

| Treatment          | Total number of differentially regulated genes | Number of upregulated genes | Number of downregulated genes |
|--------------------|-----------------------------------------------|-----------------------------|------------------------------|
| MiuA vs. control   | 779                                           | 384                         | 395                          |
| Jasplakinolide vs. control | 224                              | 132                         | 92                           |
| MiuA vs. Jasplakinolide | 101                                      | 55                          | 46                           |

Table 1. Gene regulation by MiuA (60 nM) and jasplakinolide (120 nM) after 4 h.

| GO, ID          | Term                                                  | Annotated | Significant | Expected | Fisher    |
|-----------------|-------------------------------------------------------|-----------|-------------|----------|-----------|
| GO:0071456      | cellular response to hypoxia                          | 146       | 7           | 1.09     | 0.00011   |
| GO:0030509      | BMP signaling pathway                                  | 90        | 7           | 0.67     | 0.00015   |
| GO:0030900      | forebrain development                                  | 213       | 8           | 1.6      | 0.00018   |
| GO:0045446      | endothelial cell differentiation                       | 74        | 5           | 0.55     | 0.00022   |
| GO:0007568      | aging                                                 | 194       | 7           | 1.45     | 0.0006    |
| GO:0043280      | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 92 | 5 | 0.69 | 0.00061 |
| GO:0045666      | positive regulation of neuron differentiation          | 202       | 7           | 1.51     | 0.00077   |
| GO:0043410      | positive regulation of MAPK cascade                   | 272       | 8           | 2.04     | 0.00094   |
| GO:0006935      | chemotaxis                                            | 295       | 8           | 2.21     | 0.00158   |
| GO:0032496      | response to lipopolysaccharide                         | 177       | 6           | 1.33     | 0.00267   |
| GO:0002064      | epithelial cell development                            | 124       | 5           | 0.93     | 0.00233   |
| GO:0001558      | regulation of cell growth                              | 260       | 7           | 1.95     | 0.00325   |
| GO:0071902      | positive regulation of protein serine/threonine kinase activity | 198 | 6 | 1.48 | 0.00361 |
| GO:0051051      | negative regulation of transport                      | 265       | 7           | 1.99     | 0.00361   |
| GO:0072593      | reactive oxygen species metabolic process             | 149       | 7           | 1.12     | 0.00471   |
| GO:0051216      | cartilage development                                 | 110       | 6           | 0.82     | 0.00545   |
| GO:0043405      | regulation of MAP kinase activity                     | 218       | 6           | 1.63     | 0.00576   |
| GO:0071560      | cellular response to transforming growth factor beta stimulus | 155 | 5 | 1.16 | 0.00604 |
| GO:0006979      | response to oxidative stress                          | 300       | 7           | 2.25     | 0.00706   |
| GO:0051155      | positive regulation of striated muscle cell differentiation | 31      | 5           | 0.23     | 0.00727   |

Table 2. Significant gene set enrichment (category “biological process”, Fisher’s exact test: < 0.01) based on differentially regulated genes by MiuA compared to jasplakinolide. The GOs marked in bold are unique for the comparison MiuA vs. jasplakinolide and do not show up in MiuA or jasplakinolide vs. control.
for the actin monomer. The binding free energies of MiuA within each binding site (M1 to M5) were found as: $-39.4$ kcal/mol, $-35.3$ kcal/mol, $-19.1$ kcal/mol, $-21.9$ kcal/mol and $-29.3$ kcal/mol, respectively. M1 lies in the hydrophobic cleft of the actin monomer (hydrophobic interactions with Leu110, Ile136, Ile175, Val139, and Ala170 of actin, as well as Tyr133, Phe352, Tyr143). M2 is at Lys336, M3 at Leu349 and Ile345, and M5 at Asp157. Interestingly, M4 is at Phe200 and Leu242, two binding sites for phalloidin and jasplakinolide, respectively.

For further computational studies we focused on M1, the energetically most favorable site (Fig. 6b,c). The amide oxygen atoms of the ligand form hydrogen bonds with the backbone nitrogen atoms of Ala135 and Ala170. These hydrogen bonds resemble those generally observed in secondary structure interactions of proteins, highlighting the peptidomimetic character of MiuA. There is a unique interaction between the macrocycle and the protein,

Figure 2. MiuA does not interfere with the binding of actin binding proteins to G-actin. G-actin beads were incubated with 0.01 mg/mL of the G-actin binding proteins (a) gelsolin, (b) profilin, (c) cofilin and (d) Arp2/3 complex & GST-VCA respectively, together with indicated concentrations of MiuA (molar ratio 1:10). The amount of G-actin binding protein in the pellets and supernatant was quantified. Representative images of protein bands and quantifications are shown. (Kruskal–Wallis test with Dunns test as post hoc, no significant differences vs. control, n = 3).
in which three aromatic residues from actin (Tyr133, Phe352, Tyr143) and bromophenol of the MiuA form an aromatic cyclic tetramer. To assess the influence of the docked MiuA on the stability and structure of F-actin, the equilibrated (25 ns) monomer structure was placed into an F-actin trimer scaffold structure for molecular dynamics simulations. Figure 6d,f show that for the MiuA-bound holo-complex a stable complex structure is obtained after a short equilibration time of about 20 ns, which is structurally very similar to the original build model with RMSD (root-mean-square-deviation) values oscillating around 2 Å. For the apo-complex a longer equilibration

Figure 3. MiuA selectively inhibits binding of cofilin to F-actin. (a) MiuA inhibits binding of cofilin to F-actin (upper panel), while jasplakinolide does not (lower panel). F-actin was incubated with (a) cofilin, (b) gelsolin or (c) Arp2/3 complex & GST-VCA, together with MiuA or jasplakinolide (molar ratio 1:10). Binding of gelsolin (b) or Arp2/3 (c) to F-actin were not influenced by MiuA or jasplakinolide. The amount of F-actin binding protein in the total sample, supernatant and pellets was quantified. Representative images of protein bands and quantifications are shown. (Kruskal–Wallis test with Dunns test as post hoc, **P < 0.01 vs. control, n = 3).
Figure 4. MiuA enhances actin polymerization and nucleation. (a) The pyrene assay shows an accelerated polymerization of actin after treatment with MiuA. (b) The TIRF assay shows increased number of filaments indicating more nucleation of actin upon addition of MiuA. 138 frames (control), 81 frames (MiuA 500 nM), and 60 frames (MiuA 5 µM) respectively from 3 independent experiments were evaluated. In (a) and (b) the final concentration of G-actin was 1 µM. (c) Measurement of actin nucleation by FCS: The fluorescence signal of 100 nM actin-atto488 as a function of time after 1 h incubation, without (upper left panel) and with (upper right panel) 10x molar excess of MiuA. Lower left: FCS curves of 100 nM actin-atto488 with and without MiuA. Inset: detail of the autocorrelation function at longer timescales showing the formation of larger oligomers with MiuA. Lower right: Number of spikes due to filaments diffusing through the observation volume in 10 min time intervals. The data show that up to 6 times more spikes are observed during the course of one hour in the presence of MiuA. Error bars represent the standard error of the mean of three independent measurements. (d) Actin elongation measured using TIRF microscopy. Left panel: Representative time series of fluorescence
images show the elongation of actin filaments. Right panel: The calculated actin elongation rates from 15 control and 15 MiuA treated filaments (n = 3 independent experiments). Scale bar in (b) represents 15 μm. Scale bar in (d) represents 5 μm. (Kruskal–Wallis test with Dunns test as post hoc, **P < 0.01 vs. control).

A period of about 60 ns is needed until a stable equilibrated structure is obtained (i.e. the RMSD values remain stable). This can be attributed to the fact that the final apo-structure shows larger structural deviations from the original model (overall Co·RMSD around 6 Å, Fig. 6c black line). A more detailed analysis shows that the structural changes within the individual monomers remain very small (Co·RMSD around 2 Å, Fig. 6c blue/red/magenta lines), but that there is an overall shift in the relative position of the monomers with respect to each other within the first 60 ns of the simulation (Fig. 6e). The latter can be directly observed by monitoring the distances between the center-of-masses of the individual monomer pairs (Fig. 6e). The largest movement occurs between monomers 2 and 3, whereas the distances between monomers 1–3 and 1–2 remain relatively stable. After 60 ns all distances and thus monomer positions remain stable, indicating that a stable, equilibrated apo-complex structure is reached. In the holo-structure the D loop of monomer 3 moves towards MiuA (Fig. 7a) during equilibration, forming strong interactions with the ligand. This leads to stabilization and even tightening of the monomer 2–3 interface region and thus overall stabilization of the trimeric complex (Fig. 7b). In the apo-structure the corresponding loop movement does not occur, as no ligand is present, leading to the observed shift of the monomers with respect to each other. However, analysis of overall magnitude of these changes in the apo-complex (Fig. 7b, shaded structure) and the comparison of the final structure to the original scaffold structure shows that the structural changes still remain within the experimental boundaries of the scaffold, indicating that a stable, realistic minimum was found for the apo-structure.

**Binding of cofilin to F-actin is inhibited by D-loop rearrangement.** The rearrangement of the D-loop from monomer 3 explains the tighter binding between the actin monomers 2 and 3 as MiuA stabilizes these inter-strand contacts. To investigate whether this binding might impact the interaction with cofilin, we aligned our MiuA bound structure within the cofilin bound crystal structure (PDB:3J0S16, Fig. 7c,d). This structural alignment shows that the cofilin binding site is situated adjacent to the MiuA binding site. When both MiuA and cofilin attempt to bind to F-actin simultaneously, the changes in the conformation and location of the D-loop triggered by MiuA binding lead to a partial screening of the cofilin binding site by the D-loop. This might prohibit binding of the cofilin complex and explain why cofilin competes with MiuA for binding to actin.

**Discussion**

Actin is the most abundant protein in eukaryotic cells and the protein with the greatest variety of binding partners17–19. Due to its ubiquitous expression and its many biological functions, actin has not been advanced as a clinically relevant drug target. The question how selective functional effects could be elicited by just increasing or decreasing overall actin polymerization by the use of small molecular binders in particular has precluded the use of actin targeting natural compounds in a therapeutic setting for many years in spite of their availability1,3,4. Recent years, however, it has become increasingly clear that actin-binding proteins (ABPs) are the key to localized and specific regulation of actin polymerization and depolymerization. For example, it has been shown that JMY or WHAMM are needed to localize actin nucleation specifically to the autophagosome20,21. Since the amount of G-actin in a cell is limited, a competition between actin monomers, F-actin, and ABPs for binding to the available G-actin pool takes place, and turns out to be relevant for regulation of actin function5,18,22. Exploiting this level of regulation by using the concept of “biomolecular mimicry”23 would open a new field of biological tools or even therapeutic options by developing novel and much more specific actin targeting compounds.

To date, actin binding compounds are largely classified as depolymerizers (destabilizers) or polymerizers (stabilizers). This second group consists of classical compounds like e.g. phalloidin, jasplakinolide and the chondramides, which have structural similarities and seem to share the same binding site on F-actin24. The myobacterial compound miuraenamide A (MiuA)25 is also structurally related to these compounds, and has turned out to have a functional profile similar to phalloidin or jasplakinolide (enhanced polymerization and stabilization, cell morphology and cytotoxicity)9,10. We have previously used MiuA as a bona fide actin polymerizing compound in cellular studies, and have shown effects on cell migration and transcriptional activity that can be ascribed to its actin stabilizing nature11–20. In the present study we established dose response curves for MiuA on proliferation in primary endothelial cells (HUVECs), which are similar to those in tumor cell lines8,24, and lie in the same range as those for jasplakinolide25. Interestingly, MiuA inhibited migration of HUVECs in contrast to jasplakinolide, which has been previously reported to paradoxically increase migration16,26. When we compared the effects of MiuA on transcription with those of a cellularly equipotent concentration of jasplakinolide, we detected profound differences: 101 genes were regulated in a significantly different way. Among the most significantly influenced gene ontologies annotated to these genes were some, which might in part explain the differences in migration (e.g. chemotaxis, negative regulation of transport, regulation of MAP kinase activity). Actin is able to affect transcription in multiple ways26, most of which are based on interaction of actin binding proteins with actin. Indeed, we found specific differences between MiuA and jasplakinolide concerning interaction of prototypic actin binding proteins with actin in vitro: while MiuA competed with cofilin for binding to F-actin (but not to G-actin), jasplakinolide did not. In contrast, gelsolin and Arp2/3 binding were influenced by neither compound, though they have binding sites similar to those of cofilin. Thus, there seems to be a considerable structural specificity of the inhibition.

When looking for a specific mode of action of MiuA on isolated actin in the TIRF assay and by FCS (fluorescence correlation spectroscopy), we found no surprises: nucleation and elongation were increased, F-actin
was stabilized and MiuA competed with phalloidin for binding to F-actin, which indicates binding sites of both compounds in close proximity.

However, in-silico studies revealed that MiuA binds to motifs similar and close to, but still different to the binding site of phalloidin, chondramide, or jasplakinolide. Interaction of a compound with F-actin is complex, since the compound may bind to three actin molecules at the same time at different sites. For the sake of simplicity, we collapsed all 5 binding sites of MiuA (M1 to M5), phalloidin and jasplakinolide on one monomer, respectively. This reveals that M4 is a binding site shared with phalloidin and jasplakinolide (which in part explains the competition with phalloidin), M2 and M5 also show similar binding sites as phalloidin and jasplakinolide, but M1 and M3 address sites in the actin molecule, which are not bound by the other F-actin stabilizing compounds. The mode of binding to this site is unique in that the bromophenol substitution of the macrocycle and the three aromatic residues from actin (Tyr133, Phe352, Tyr143) form an aromatic cyclic tetramer. Similar motives (involving more or less aromatic cycles) were shown to be frequently observed in proteins and contribute to the stabilization of their tertiary structures. This relatively strong interaction (about 5 kcal/mol in vacuum) reveals the importance of the bromophenol ring as a crucial moiety of the macrocyclic MiuA. The second phenyl ring bound to the macrocycle, on the other hand, is not engaged in any crucial interactions.

Analysis of the influence of MiuA binding on the F-actin structure by simulation of actin-trimer complexes with and without bound MiuA showed that the binding of MiuA influences the overall structures of the actin timer, as for the apo-actin-trimer a different relative arrangement of the individual actin monomers was observed compared to the holo-trimer complex. A more detailed analysis of the structures revealed that the MiuA ligand bound to the actin DNAse I binding site triggers the migration of the D-loop in monomer 3 towards actin. This phenomenon increases the contact area between the monomers. Presumably MiuA further acts as a buffer between these two monomers and stabilizes the compact trimer form. Comparisons between holo- and apo-structures show that the interaction between monomers 2 and 3 is affected most by the binding of MiuA, although all monomers contain a ligand in the holo-system. This is consistent with the fact that only the ligand of monomer 2 is located at an inter-monomeric interface in the trimer simulation. This observation, together with the RMSD analysis, further highlights that the binding of MiuA does not affect the individual integrity of

Figure 5. MiuA stabilizes F-actin and competes with phalloidin for binding to F-actin. (a) MiuA decelerates depolymerization of F-actin as shown by TIRF microscopy. Left panel: Representative fluorescence images at different time points during F-actin depolymerization. Right panel: The average length of actin filaments was quantified as depolymerization parameters. Scale bar: 15 µm. (b) MiuA competes with phalloidin for binding to actin filaments. Atto488 labeled F-actin was incubated with 16.5 nM rhodamine phalloidin and increasing concentrations of MiuA. Images of actin filaments were taken by TIRF microscopy. Left panel: TIRF images showing the Atto488-labeled actin filaments (upper panels) and rhodamine-labeled phalloidin (lower panels). At increasing concentrations of MiuA, the binding of phalloidin to actin filaments decreased. Right panel: The red fluorescence of actin filaments was quantified and an IC50 of MiuA was calculated (n = 3). Scale bar: 15 µm.
the units but regulates the inter-monomeric interactions. Overall, MiuA binding ensures a tighter and stronger packing of the actin monomers compared to the apo F-actin by shifting the D-loop, which is indispensable for F-actin stabilization. Our molecular dynamics simulations also offer an explanation for the inhibition of cofilin binding by MiuA: the shift of the D-loop by MiuA leads to a clash between this loop and cofilin in its bound conformation.

The transcriptional differences between MiuA and jasplakinolide might in part be linked to the effects of MiuA on binding of cofilin to F-actin, since cofilin directly modulates nuclear architecture, but also plays an important role in regulating nuclear actin levels, which, in turn, have an influence on transcriptional regulation. Our finding that the co-localization of cofilin and F-actin is decreased in cells treated with MiuA supports the hypothesis that this competition indeed occurs in the cellular context. However, due to the complexity of the role of actin and actin binding proteins in transcriptional regulation, we cannot rule out other modes of action of MiuA treatment.

Though MiuA has been termed to be structurally similar to jasplakinolide, we identified a unique mode of action that selectively inhibits binding of cofilin to F-actin and causes transcriptional regulation different from
that of jasplakinolide. Consequently, we reveal that small structural differences in actin binding compounds can cause functional selectivity, which was not presumed in this class of molecules. The much better synthetic accessibility of MiuA, as compared to other actin stabilizing compounds, makes it an ideal candidate for studying structure-activity relationships. Ideally, it could be feasible to create derivatives that do not influence actin polymerization per se, but selectively modulate the binding of single actin-binding proteins, and circumvent the selectivity issues, which have hindered the development of actin-modulating drugs.

Figure 7. Model for the compaction of the actin trimer and for the replacement of coflin by the movement of the D-loop. (a) The orientation of MiuA within the trimer is depicted with an additional focus on the interaction between the D-loop of monomer 3 and the ligand of monomer 2 in the inset. (b) The difference in packing between the apo- (transparent coloring) and holo- (solid coloring) trimer systems is illustrated for a representative structures of the two complexes. (c) Once MiuA binds to F-actin, the D-loop of monomer 2 moves closer to monomer 1 during the molecular dynamics simulation. (d) MiuA and coflin bound to the F-actin (the position of coflin is shown as bound in the apo-structure with F-actin). The new conformation of the D-loop overlaps with the bound conformation of coflin. (e) Actin binding sites for MiuA, phalloidin and jasplakinolide. Five potential binding sites for MiuA (M1 to M5) obtained by the computer-based docking simulations are projected into the G-actin monomer (PDB: 3HBT). G-actin: magenta, respective binding sites of the other compounds according to literature: yellow.
Methods

Compounds. Miuraenamide A (MiuA) was synthetized as described previously. For the experiments MiuA was dissolved and stored in DMSO (dimethyl sulfoxide). Jasplakinolide was purchased from Santa Cruz (Heidelberg, Germany). For all experiments with compounds respective solvent controls with a matching concentration of DMSO were performed (termed “control”).

Proliferation assay. HUVECs (human umbilical vein endothelial cells) were purchased from Promocell, Heidelberg, Germany, and cultured with endothelial growth medium (Promocell), supplemented with 10% FCS under constant humidity at 37 °C and with 5% CO2. Upon confluency, cells were split in a ratio 1:3 in T25 flasks. Cells were used for functional assays at passage 6. 1.5 × 10⁶ cells/well were seeded in 96-well plates. After 24 h, cells were treated with the indicated concentrations of MiuA and incubated for further 72 h. Subsequently, cells were stained with 100 µL/well Crystal Violet solution (0.5% Crystal Violet and 20% methanol in H2O) for 10 min, then washed with H2O and dried. Finally, 100 µL/well Na-citrate solution (50% ethanol, 50% 0.1 M Na-citrate in H2O) were added, incubated on a shaker for 5 min and measured at 550 nm using a microplate reader (Sunrise, Tecan, Maennedorf, Switzerland).

Fluorescence imaging. HUVECs (1.5 × 10⁶ cells/well) were seeded in ibidi µ slides (ibidi GmbH, Munich, Germany), treated with MiuA as indicated for 1 h, and subsequently fixed with 4% (v/v) paraformaldehyde. F-actin was stained with rhodamine phalloidin (1:400, R 415, Molecular Probes, Life technologies) and nuclei were labeled with Hoechst stain (bisBenzimide H33342 trihydrochloride, B2261 Sigma-Aldrich). Images were taken using a Zeiss LSM 510 META confocal microscope (Zeiss, Jena, Germany). For the co-localization experiments cells were treated for 30 min with 50 nM MiuA, and subsequently stained as described above with the addition of an anti-cofilin antibody (D3F9, rabbit, Cell Signaling), and a subsequent step of incubation with an Alexa488 labelled secondary antibody (goat anti rabbit, A – 11008, Invitrogen). These images were obtained on an inverted SP8 confocal microscope (Leica, Germany).

Scratch assay. Confluent HUVECs were scratched with a custom made tool and treated with the indicated concentrations of MiuA. Cells were allowed to migrate for 16–24 h, then washed with 100 µL/well PBS (including Mg²⁺, Ca²⁺), stained with 100 µL/well Crystal Violet solution for 10 min, washed with water, and dried. Images were collected using an inverted microscope (Zeiss Axiovert 100). Image analysis was performed with ImageJ. Migration was quantified as the percentage of cell-covered area compared with the total image area.

2D and 3D chemotaxis. For the 2D-chemotaxis assay, HUVECs (50 × 10⁶/well) were seeded in a µ-Slide Chemotaxis ibiTreat (ibidi GmbH, Munich, Germany), treated with MiuA as indicated for 2 h. Then a gradient of FCS between 0 and 10% (v/v) was applied to the slide according to the manufacturer’s instructions. For the 3D-chemotaxis assay, HUVECs (50 × 10⁶/well) were seeded in matrigel (REF 356231, Corning, Matrigel® Basement Membrane Matrix Growth Factor Reduced, Phenol Red Free, *LDEV-Free) in a µ-Slide Chemotaxis3D ibiTreat, treated as indicated and incubated. After 0.5 h, a gradient FCS between 0 and 10% (v/v) was applied. Time lapse image sequences of cell migration were collected every 10 min for 20 h using an inverted Nikon microscope (Eclipse), equipped with a custom made incubation chamber. Images were analyzed using the Chemotaxis and Migration Tool (Version 2.0 with ImageJ Plugin). Cell mean velocity, directness and the X-forward migration index (FMI) were calculated.

G-actin binding assay. All actin binding proteins were purchased from Hypermol, Bielefeld, Germany. They were either produced recombinantly (cofilin, profiling) or isolated from porcine tissue (gelsolin, Arp2/3). The G-actin binding assay was performed using the ‘Actin-Toolkit G-Actin Binding’ (Hypermol). In this kit, G-actin is coupled to SepharoseTM as G-actin beads. Binding of actin-binding proteins (ABPs) to G-actin is highly specific, and thus, the ABPs bound to G-actin are co-precipitated under low centrifugal forces. G-actin beads (1/4 volume of 1 tube) were pretreated with MiuA (20 µM) for 30 min at room temperature under agitation, then the respective ABPs were added, and incubated for 1 h at RT. After incubation, the sample was spun at 6,000 × g at 4 °C for 4 min and 40 µL supernatant were prepared for an SDS-gel. The G-actin beads were washed, boiled, and resuspended in 25 µL of 1 × SDS-sample buffer. Both, the supernatant and the G-actin beads were separately loaded onto a SDS-PAGE gel. After electrophoresis, the gel was imaged using a ChemiDoc Imaging System (Bio–Rad Laboratories, Munich, Germany). The amount of each protein was quantified using the Image Lab 6.0 Software. Since binding of gelsolin is Ca²⁺ dependent, the binding assay was carried out in the presence of 200 µM CaCl₂ in this case. As control for unspecific binding of proteins, uncoupled beads were used (Supplementary Fig. 1a), gelsolin was used in the absence and presence of Ca²⁺ (Supplementary Figure 1a), and gelsolin and cofilin were used in a competition experiment (Supplementary Fig. 1b).

F-actin binding assay. The F-actin binding assay was performed using the ‘Actin-Toolkit F-Actin Binding’ (Hypermol, Bielefeld, Germany). F-actin was prepared by polymerizing G-actin with polymerization buffer for 30 min at room temperature. 250 µL of an F-actin sample mix were prepared by incubating F-actin with MiuA for 30 min in PolyMix (100 mM KCl, mM MgCl₂, 1 mM ATP, 10 mM imidazole pH 7.4) at room temperature. The respective F-actin binding protein was then added and incubated for 1 h at room temperature (the molar ratio of F-actin, MiuA (or jasplakinolide) and actin binding protein was 1:10:1). After incubation, 40 µL of the sample mix were prepared for a total SDS-PAGE sample. Pelleting of F-actin binding proteins was achieved by spinning the rest of the sample at 100,000 × g, at 4°C for 1 h. 40 µL of the supernatant were prepared as a sample for SDS-PAGE. The pellets were dissolved in 200 µL of 1 × SDS-sample buffer, boiled and then each SDS-sample (total, supernatant and pellet) was loaded onto a SDS-PAGE gel separately to observe F-actin binding after electrophoresis. The
Assessment of the transcriptome. HUVECs at 80% confluence were treated with equipotent concentrations of MiuA or jasplakinolide (60 nM and 120 nM respectively) for 4 h. The concentrations were chosen in order to stay below levels causing visible alterations of cell morphology and overall actin structure. mRNA was cleaned up from cell lysates with Sera-Mag carboxylated magnetic beads (Thermo Fisher, Waltham, MA, USA) and reversely transcribed using a slightly modified SCRB-seq protocol [41]. During reverse transcription, sample-specific barcodes and unique molecular identifiers were incorporated into first strand cDNA. Next, samples were pooled and excess primers digested by Exonuclease I (Thermo Fisher, Waltham, MA, USA). cDNA was preamplified using KAPA HiFi HotStart polymerase (KAPA Biosystems). Sequencing libraries were constructed from cDNA using the Nextera XT Kit (Illumina, San Diego, CA, USA). Resulting libraries were quantified and sequenced at 10 nM on a HiSeq1500 (Illumina, San Diego, CA, USA). To obtain gene-wise expression values, raw sequencing data was processed using the zUMIs pipeline [34] using the Human genome build hg19 and Ensembl gene models (GRCh37.75). Transcriptome analysis was performed using the free statistical software R (v. 3.4.2). DESeq2 package (v.1.16.1) was used for normalization and differential expression (DE) analysis. DESeq2 models transcriptional count data using negative binomial distribution. Additional filtering was done using HTSFilter (v.1.16.0) to remove constant, lowly expressed genes. The final gene set consisted of 13 232 genes.

DE testing was based on Wald test. Multiple testing was accounted for by applying a global false discovery rate (FDR) correction to all comparisons. All genes with FDR < 0.1 were considered significant.

Enrichment analysis for Gene Ontology terms was performed using topGO package (v.2.28.0), specifying the ontology of Biological Processes (BP). Fisher’s exact test was applied to measure the significance of enrichment.

Pyrene assay. Pyrene actin was purchased from Hypermol (Bielefeld, Germany) and diluted to a 1 mg/mL (24 μM) stock solution. Before use, spontaneously formed actin aggregates were removed by ultracentrifugation for 1 h at 40,000 rpm and 4°C. 50 μL samples for the pyrene assay consisted of: 30 μL H2O, 10 μL 10 mM MgCl2 or 250 mM KCl, 5 μL F-actin buffer (100 mM Imidazole-Cl pH 7.4, 10 mM ATP, Hypermol, Germany) as well as 5 μL DMSO (containing the indicated concentrations of MiuA). 10 μL pyrene actin (end concentration 1 μM) were rapidly added to start polymerization. Pyrene fluorescence was monitored at 400 nm every 20 s over 1 h in a 96-well fluorescence plate reader (Tecan) with 360 nm excitation.

TIRF assays. Flow cells containing 15–20 μL of fluid were prepared as a sandwich of a cover slip (22 × 22 mm), two parafilm strips forming an approximately 5 mm wide channel, and a glass microscope slide (76 × 26 mm).

Atto488-actin and actin (unlabeled) from rabbit skeletal muscle were purchased from Hypermol (Bielefeld, Germany). Labeled actin was prepared by mixing Atto488-actin and actin 1:1 v/v. A stock solution of r-actinin from turkey gizzard smooth muscle (Hypermol, Bielefeld, Germany) was prepared by adding 1 mL H2O to the tube with α-actinin to obtain a working stock of 1 mg/mL. α-actinin was used as tethering protein for actin filaments, since it has turned out to alter filament structure and dynamics least [42].

Nucleation and polymerization assay. Freshly prepared flow cells were first incubated with 25 μL 1% (w/v) bovine serum albumin (BSA). After 10 min, 25 μL α-actinin (1 mg/mL) was applied into the flow cell and incubated for 5 min. In the meantime, labeled actin (10 μM) was incubated 1:1 with 1:10 volume of 10 × Mg exchange buffer (400 μM MgCl2, 2 mM EGTA) and 1:8 with G-buffer (2 mM Tris-HCl, pH 8.0, 0.2 mM CaCl2, 0.5 mM DTT, 0.2 mM ATP, final pH 7.8) for 5 min on ice to convert Ca-ATP-actin to Mg-ATP-actin. Flow cells were then washed with 30 μL of G-buffer. 2 × Mg-ATP-actin (1 μM) was mixed 1:1 with 2 × TIRF buffer (100 mM KCl, 2 mM MgCl2, 2 mM EGTA, 30 mM imidazole, 30 mM D-glucose, 40 μg/mL catalase, 400 μg/mL glucose oxidase, 1% methylcellulose, 2% β-mercaptoethanol, final pH 7.4) containing MiuA as indicated, and the polymerization started. 30 μL of polymerizing actin were immediately loaded into the flow cell chamber and placed on the TIRF microscope (Leica Microsystems, Wetzlar, Germany) to start image acquisition. The amount of actin nuclei present in each frame was analyzed using programs custom-written in MATLAB (The MathWorks, Natick, MA) R2017a. For polymerization assays, fluorescence image sequences of actin polymerization were taken every 1 s for 5 min. Elongation rates were calculated by Image J software (version 1.49).

Depolymerization assay. Labeled F-actin was obtained by incubating labeled actin (10 μM) 1:1 with 1:10 volume of 10 × polymerization buffer and 1:8 with G-buffer for 1 h at room temperature. 20 μL 1:4 diluted F-actin (with G-buffer) was loaded into a flow cell previously blocked with 1% BSA and coated with 1 mg/mL α-actinin. Then, 50 μL of 1 × TIRF buffer with 5 μM MiuA were gently applied into the flow chamber. The sample was immediately placed on the TIRF microscope and data acquisition was started. Actin depolymerization was followed in time by collecting individual frames every 15 s over 90 min.

Phalloidin competition assay. Rhodamine-phalloidin was purchased from Invitrogen. For the phalloidin competition assay, labeled F-actin (prepared as described above) was loaded into a freshly coated flow cell. TIRF buffer with 16.5 nM rhodamine-phalloidin and different concentrations of MiuA were applied as indicated into the flow chamber and immediately placed on the TIRF microscope to start image acquisition. Different regions of interest were measured. Fluorescence from the actin filaments were recorded in the green channel while the signal from rhodamine-labeled phalloidin was monitored in the red channel. The change in intensity of the rhodamine-labeled phalloidin (Δintensity) and the IC 50 of the displacement reaction were calculated using ImageJ software (version 1.49) and Prism software, respectively.
Fluorescence correlation spectroscopy. FCS experiments were performed on a home-built confocal fluorescence set-up. LabTek slides were incubated with 10% BSA for 10 min. Atto488 labeled actin (99% labeled, Hypermol, Bielefeld, Germany) was incubated in Mg exchange buffer for 5 min on ice, then polymerization was started by adding KMEI buffer (100 mM KCl, 2 mM MgCl$_2$, 2 mM EGTA, 30 mM imidazole) to a final actin concentration of 50 or 100 nM. FCS measurements were taken for 1 h in 10 min time intervals. FCS curves were plotted using PAM (PIE analysis with MATLAB, The MathWorks, MA, USA). The spike occurrence and intensity were analyzed using self-written code in MATLAB. A peak was considered a spike when the intensity was higher than the mean count rate of the measurement plus 4 times the standard deviation.

Docking studies. Structure Preparation. The MiuA structure was built using the Avogadro program. The actin structure was taken from PDB-ID 1NWK, where actin was crystallized in the presence of an ATP molecule and calcium ions. ATP was converted into ADP and the calcium ion was kept within the model system. The actin trimer was built using the structure from the PDB code 3J8A as a scaffold. Three replicas of the miuraenamide A bound monomer complexes were placed into this scaffold (see below for the complex formation). Missing hydrogen atoms of the actin proteins and ADP were added using the tleap module of the Amber14/AmberTools package. Each molecular system prepared in this work was solvated within a box of TIP3P water molecules by applying a 12 Å buffer region.

Parameters. The ff03 force field parameters were chosen for the protein atoms. The ADP parameters by Carlson and coworkers were used. For the ligands, the General Amber Force Field (GAFF) parameters were chosen and the charges were calculated using the following stepwise strategy to obtain a precise set of atomic point charges: (i) Initially, atomic charges were calculated using the AM1 level and the bcc model as implemented in the antechamber module of AmberTools15, (ii) Molecular dynamics simulations were performed for 500 ns at 300 K in gas phase using these initial charges, (iii) the structures along the trajectory were clustered and the representative conformations of each cluster were optimized using the Gaussian09 program package (Gaussian Inc., Wallingford, CT, USA) (HF/6–31 G(d,p) level of theory) (iv) the electrostatic potential of the energetically most favorable conformation was calculated at the B3LYP/cc-pVTZ level of theory and the point charges were derived using the RESP procedure.

Molecular dynamics simulations. The same minimization and heat up procedure as described in our previous publications was applied to all of the modeled systems. The box size was gradually adjusted trough a sequential series of energy minimizations performed with the sander module of Amber to reach a target density of 1.0 g/cm$^3$. The systems were first heated up from 0 to 50 K by applying a 3.0 kcal.mol$^{-1}$.Å$^{-2}$ restraint to the Cartesian position of all protein non-hydrogen atoms. The constraint was then reduced to affect only the backbone atoms while heating the system from 50 to 200 K. All restraints were then released while the temperature was increased to 300 K. The SHAKE algorithm was used to constraint all bonds involving hydrogen atoms. Long-range electrostatic interactions were calculated using the standard settings of the particle mesh Ewald method. Periodic boundary conditions were applied to each system. Temperature and pressure were controlled by the Langevin thermostat (collision frequency of 4.0 ps$^{-1}$) and Berendsen barostat (default Amber settings), respectively. The integration time step was set to 1 fs and a non-bonded cutoff of 12 Å was applied for non-bonded interactions. The simulations were performed using the cuda-enabled graphics processing units (GPUs) version of the pmemd module of Amber14. After equilibration (see above) simulations were performed for 25 ns and 150 ns, for the MiuA bound actin monomer and for the MiuA bound trimer (holo), respectively. After building the MiuA bound structure on the F-actin scaffold (see Structure Preparation), the three ligands were removed from the complex (apo) and a 150 ns long MD simulation was run for this system as a control.

Conformational sampling of miuraenamide. MiuA was solvated in a box of water using the same protocol as introduced above. A protocol similar to that described above was used for heating up the system, however slightly modified to reach a target temperature of 370 K (i.e., two steps were added to the temperature ramp: 340 K and 370 K). Three parallel molecular dynamics simulations of 250 ns each were performed for each ligand at 370 K, starting from a different set of random velocities, thus reaching 750 ns of sampling per ligand. The conformations of each ligand were clustered along their respective 750 ns sampling trajectory using a RMSD-based hierarchical clustering as implemented in cpptraj with a target number of five clusters.

Molecular docking calculations. Broad sampling and subsequent refinement of the binding positions were performed using the DynaDock procedure as implemented in our in-house modeling program (DynaCell). As the binding site of the ligand is unknown, five distinct binding sites were tested. These sites were chosen based on a combination of experimental information obtained in the current study, prior knowledge on binding site of other examples of the actin stabilizing macrocyles and surface based visual analysis done by pymol. Five representative conformations of the ligands were used as starting structures for docking at each of the five chosen binding sites. The internal structure of the ligands was kept fixed during the broad sampling while the translational and rotational degrees of freedom of the ligand within the binding pocket were flexible, allowing, a maximum translation step of 2 Å (in all three Cartesian directions) and a rotational angle step of 30°. The van der Waals radii of the receptor and ligand atoms were allowed 80% of overlap to implicitly treat potential induced fit-based adaptations within the binding site. The sampling was continued until 2000 poses were collected. These 2000 poses were further analyzed based on the overall position of the ligand (within a 15 Å radius from the active site) and its relative position to the other poses (maximum distance of 4 Å). This analysis yielded approximately 250 poses, which were further refined using a softcore-based potential and specialized MD algorithm (OPMD), as
implemented in DynaCell. OPMD simulations were performed for 20 ps using backbone restraints with a force constant of 100 kJ mol\(^{-1}\) nm\(^{-2}\). The side chain atoms of the protein and all atoms of the ligands remained free for flexible conformational adaption of the binding site to the sampled ligand pose (induced-fit phenomenon). Structures within the remaining van der Waals overlap were characterized as successful poses and a total of approximately 400 refined poses were obtained for each of the five starting conformations of the ligand in each of the five explored binding sites. Afterwards, the resulting poses were clustered based on their RMSD (only non-hydrogen atoms) with a maximum distance of 2 Å between the clusters. Following the clustering analysis, the two best-ranked poses from the first three clusters were selected, if three or more different cluster were observed. This detailed protocol (including both broad sampling and the refinement) was applied to model each of the five possible binding sites (M1-M5). Combining the chemical interaction analysis (as detailed in the Results section) with the short stability analysis (results not shown), the binding site M1 was chosen as the most probable binding site and further calculations were performed on the complex with MiuA bound in this region.

**Binding energy calculations.** Each binding mode was equilibrated for 5 ns using the same MD scheme as above. Three distinct simulations (each starting with different velocities) were performed on equilibrated structures for further 15 ns. The time step was 1 fs. A total of 225,000 complex frames (3 × 75,000) were saved during 15 ns simulation. The binding free energies were estimated using the Molecular Mechanics-Generalized Born Surface Area (MMGBSA) approach\(^{28}\) by means of the MMGBSA.py module\(^{29}\) of Amber16/AmberTools17.\(^{20}\) The contribution of the solvent was computed using the default Generalized Born Surface Area (GBSA) options of the script with a probe radius of 1.4 Å and the ‘mbondi2’ radii set\(^ {41}\).

**Statistical analysis.** Quantitative data are expressed as mean ± SEM. Statistical analysis was performed using the software GraphPad Prism Version 7.02 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical differences were evaluated by using Kruskal–Wallis test or one-way analysis of variance (ANOVA). P-values less than 0.05 were considered to be significant. For all tests, three replicates from three independent experiments (n = 3) were used. Specific information on the statistical procedures used can be found in the respective figure legends.

**Data Availability**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**References**

1. Katagiri, K. & Matsuura, S. Antitumor activity of cytochalasin D. *J Antibiot (Tokyo)* 24, 722–723 (1971).
2. Low, I., Dancker, P. & Wieland, T. Stabilization of F-actin by phalloidin. Reversal of the destabilizing effect of cytochalasin B. *FEBS Lett* 26, 263–265 (1975).
3. Spector, I., Shochet, N. R., Kashman, Y. & Groweiss, A. Latrunculins: novel marine toxins that disrupt microfilament organization in cultured cells. *Science* 219, 493–495 (1983).
4. Bubb, M. R., Senderowitz, A. M., Sausville, E. A., Duncan, K. L. & Korn, E. D. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. *J Biol Chem* 269, 14869–14871 (1994).
5. Davidson, A. J. & Wood, W. Unravelling the Actin Cytoskeleton: A New Competitive Edge? *Trends Cell Biol* 26, 569–576, https://doi.org/10.1016/j.tcb.2016.04.001 (2016).
6. Goldschmidt-Clermont, P. J. et al. The control of actin nucleotide exchange by thymosin beta 4 and profilin. A potential regulatory mechanism for actin polymerization in cells. *J Mol Biol Cell* 3, 1015–1024, https://doi.org/10.1016/j.molcel.1992.03.015 (1992).
7. Miralles, F., Posern, G., Zaromytidou, A. I. & Treisman, R. Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell* 113, 329–342 (2003).
8. Klenchin, V. A. et al. Trisoxazole macrolide toxins mimic the binding of actin-capping proteins to actin. *Nat Struct Biol* 10, 1058–1063, https://doi.org/10.1038/sub1006 (2003).
9. Karmann, L., Schulz, K., Herrmann, J., Müller, R. & Karmacier, U. Total synthesis and biological evaluation of miuraenamides. *Angewandte Chemie International Edition* 54, 4502–4507 (2015).
10. Sumiya, E. et al. Cell morphology profiling of a natural product library identifies bisebromomide and miuraenamide A as actin filament stabilizers. *ACS chemical biology* 6, 425–431 (2011).
11. Moser, C. et al. Persistent inhibition of pore-based cell migration by sub-toxic doses of miuraenamide, an actin filament stabilizer. *Sci Rep* 7, 16407, https://doi.org/10.1038/s41598-017-16759-7 (2017).
12. Lee, E., Shelden, E. A. & Knecht, D. A. Formation of F-actin aggregates in cells treated with actin stabilizing drugs. *Cell Motil Cytoskeleton* 39, 122–133, https://doi.org/10.1002/(SICI)1097-0169(1998)39:2<122::AID-CM3>3.0.CO;2-8 (1998).
13. Crevenna, A. H. et al. Electrostatics control actin filament nucleation and elongation kinetics. *J Biol Chem* 288, 12102–12113, https://doi.org/10.1074/jbc.M113.456327 (2013).
14. Mentes, A. et al. High-resolution cryo-EM structures of actin-bound myosin states reveal the mechanism of myosin force sensing. *Proc Natl Acad Sci USA* 115, 1292–1297, https://doi.org/10.1073/pnas.1718316115 (2018).
15. Merino, F. et al. Structural transitions of F-actin upon ATP hydrolysis at near-atomic resolution revealed by cryo-EM. *Nat Struct Mol Biol* 25, 528–537, https://doi.org/10.1038/s41594-018-0074-z (2018).
16. Galkin, V. E. et al. Remodeling of actin filaments by ADF/cofilin proteins. *Proc Natl Acad Sci USA* 108, 20568–20572, https://doi.org/10.1073/pnas.1110109108 (2011).
17. Dominguez, R. Actin-binding proteins--a unifying hypothesis. *Trends Biochem Sci* 29, 572–578, https://doi.org/10.1016/j.tibs.2004.09.004 (2004).
18. Povarova, O. I., Uversky, V. N., Kuznetsova, I. M. & Turoverov, K. K. Actinous enigma or enigmatic actin: Folding, structure, and functions of the most abundant eukaryotic protein. *Intrinsically Disord Proteins* 2, e34500, https://doi.org/10.4161/idp.34500 (2014).
19. Xue, B. & Robinson, R. C. Guardians of the actin monomer. *Eur J Cell Biol* 92, 316–332, https://doi.org/10.1016/j.ejcb.2013.10.012 (2013).
20. Coutts, A. S. & La Thangue, N. B. Actin nucleation by WH2 domains at the autophagosome. *Nat Commun* 6, 7888, https://doi.org/10.1038/ncomms8888 (2015).
21. Kast, D. J., Zajac, A. L., Holzbaur, E. L., Ostap, E. M. & Dominguez, R. WHAMM Directs the Arp2/3 Complex to the ER for Autophagosome Biogenesis through an Actin Comet Tail Mechanism. *Curr Biol* 25, 1791–1797, https://doi.org/10.1016/j.cub.2015.05.042 (2015).
Acknowledgements
The authors gratefully acknowledge the financial support by the Chinese Scholarship Council and the German Research Foundation (DFG), SFB1032 project B08 (to S.Z.), SFB1032 project B03 (to D.C.L.), SFB749 project C08 (to I.A.), and SFB1035 project A10 (to I.A.). A.H.C. acknowledges the support by the Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular) funded by FEDER funds through COMPETE2020 - Programa Operacional Competitividade e Internacionalização (POCI) and by national funds through FCT - Fundação para a Ciência e a Tecnologia. A.V. and U.K. were supported by the DFG (FOR1406). D.C.L. gratefully acknowledges support of the Ludwig-Maximilians-Universität through the Center for NanoScience (CeNS) and the LMUinnovativ program BioImaging Network (BIN).

Author Contributions
S. Wang, M. Hoyer, F. Gegenfurtner, Z. Kliesmete and C. Ziegenhain performed research, A.H. Crevenna, I. Ugur and Antoine Marion analyzed data, U. Kazmaier contributed new reagents, I. Antes, D.C. Lamb, W. Enard, A. Vollmar and Stefan Zahler designed research, A.H. Crevenna, I. Antes, D.C. Lamb and Stefan Zahler wrote the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46282-w.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019